SEC filings and other documents

Operational discipline and portfolio expansion drive growth, with cash flow breakeven targeted for Q4 2026.

PermeaDerm delivers major cost savings, workflow benefits, and clinical outcomes on par with allograft.

Guidance raised to $86-$89M, with cash flow breakeven targeted for Q4 and strong growth momentum.

Revenue growth, margin stability, and product adoption drive confidence in sustained expansion.

Q2 revenue up 18% year-over-year; 2026 guidance raised, cash flow breakeven expected Q4.

Sequential revenue growth, strong margins, and reaffirmed guidance signal renewed momentum.

Revenue rose 4% year-over-year to $19.3M, with improved margins and reaffirmed guidance.

Cohealyx reduces grafting time by nearly 20 days, driving faster healing and high surgeon satisfaction.

Accelerating growth in acute wound care with innovative products and expanding market penetration.

2026 guidance targets $80–$85M revenue, with renewed focus on growth, execution, and profitability.

2026 revenue is projected at $80–$85 million, driven by clinical innovation and focused execution.

2026 revenue expected to rise 12–19% as reimbursement clarity boosts multi-product adoption.

Reimbursement recovery and cost discipline set the stage for renewed growth in 2026.

Growth strategy centers on U.S. account expansion, operational discipline, and renewed reimbursement momentum.

Q3 revenue fell 13% year-over-year, but cost controls and reimbursement gains support future growth.